265 related articles for article (PubMed ID: 18612551)
1. Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab.
Hagel S; Jantsch J; Budde U; Kalden JR; Eckardt KU; Veelken R
Thromb Haemost; 2008 Jul; 100(1):151-3. PubMed ID: 18612551
[No Abstract] [Full Text] [Related]
2. Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS13 inhibitor.
Schleinitz N; Ebbo M; Mazodier K; Poullin P; Bernit E; Veit V; Veyradier A; Fakhouri F; Kaplanski G; Harle JR
Am J Hematol; 2007 May; 82(5):417-8. PubMed ID: 17266057
[No Abstract] [Full Text] [Related]
3. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
Scully M; Cohen H; Cavenagh J; Benjamin S; Starke R; Killick S; Mackie I; Machin SJ
Br J Haematol; 2007 Feb; 136(3):451-61. PubMed ID: 17233847
[TBL] [Abstract][Full Text] [Related]
4. Recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab.
Herbei L; Venugopal P
Clin Adv Hematol Oncol; 2006 Mar; 4(3):215-7; discussion 217-8. PubMed ID: 16728931
[No Abstract] [Full Text] [Related]
5. Efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura.
Hull MJ; Eichbaum QG
Clin Adv Hematol Oncol; 2006 Mar; 4(3):210-4; discussion 217-8. PubMed ID: 16728930
[No Abstract] [Full Text] [Related]
6. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
Bresin E; Gastoldi S; Daina E; Belotti D; Pogliani E; Perseghin P; Scalzulli PR; Paolini R; Marcenò R; Remuzzi G; Galbusera M
Thromb Haemost; 2009 Feb; 101(2):233-8. PubMed ID: 19190804
[TBL] [Abstract][Full Text] [Related]
7. Current insight into thrombotic thrombocytopenic purpura.
Verbeke L; Delforge M; Dierickx D
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):3-10. PubMed ID: 19851089
[TBL] [Abstract][Full Text] [Related]
8. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.
Zheng X; Pallera AM; Goodnough LT; Sadler JE; Blinder MA
Ann Intern Med; 2003 Jan; 138(2):105-8. PubMed ID: 12529092
[TBL] [Abstract][Full Text] [Related]
9. Thrombotic thrombocytopenic purpura: from the bench to the bedside, but not yet to the community.
George JN; Vesely SK
Ann Intern Med; 2003 Jan; 138(2):152-3. PubMed ID: 12529099
[No Abstract] [Full Text] [Related]
10. Summaries for patients. Treatment of refractory thrombotic thrombocytopenic purpura.
Ann Intern Med; 2003 Jan; 138(2):I38. PubMed ID: 12529111
[No Abstract] [Full Text] [Related]
11. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.
Pandey S; Nakagawa M; Rosenbaum ER; Arnaoutakis K; Hutchins LF; Makhoul I; Milojkovic N; Cottler-Fox M
J Clin Apher; 2015 Feb; 30(1):50-4. PubMed ID: 25042026
[TBL] [Abstract][Full Text] [Related]
12. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
Sadler JE
Blood; 2008 Jul; 112(1):11-8. PubMed ID: 18574040
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).
Ahmad A; Aggarwal A; Sharma D; Dave HP; Kinsella V; Rick ME; Schechter GP
Am J Hematol; 2004 Oct; 77(2):171-6. PubMed ID: 15389904
[TBL] [Abstract][Full Text] [Related]
14. Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura.
Kosugi S; Matsumoto M; Ohtani Y; Take H; Ishizashi H; Fujimura Y; Kuyama J
Int J Hematol; 2005 Jun; 81(5):433-6. PubMed ID: 16158827
[TBL] [Abstract][Full Text] [Related]
15. A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura.
Foley SR; Webert K; Arnold DM; Rock GA; Clark WF; Barth D; Sutton DM;
Kidney Int Suppl; 2009 Feb; (112):S55-8. PubMed ID: 19180138
[TBL] [Abstract][Full Text] [Related]
16. A 9-month-old infant with acquired idiopathic thrombotic thrombocytopenic purpura caused by inhibitory IgG-autoantibody to ADAMTS13.
Sato A; Hoshi Y; Onuma M; Sato R; Tsunematsu Y; Isonishi A; Matsumoto M; Fujimura Y; Imaizumi M
Pediatr Hematol Oncol; 2010 Feb; 27(1):53-8. PubMed ID: 20121555
[TBL] [Abstract][Full Text] [Related]
17. [Rituximab as effective therapy in very severe thrombotic thrombocytopenic purpura (TTP)].
Illner N; Wolf G
Dtsch Med Wochenschr; 2010 May; 135(3):71-4. PubMed ID: 20077379
[TBL] [Abstract][Full Text] [Related]
18. [Successful treatment of thrombotic thrombocytopenic purpura (TTP) with rituximab].
Arici B; Trendelenburg M
Ther Umsch; 2008 Dec; 65(12):710-2. PubMed ID: 19048526
[TBL] [Abstract][Full Text] [Related]
19. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine.
Böhm M; Betz C; Miesbach W; Krause M; von Auer C; Geiger H; Scharrer I
Br J Haematol; 2005 Jun; 129(5):644-52. PubMed ID: 15916687
[TBL] [Abstract][Full Text] [Related]
20. Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab.
Goyal J; Adamski J; Lima JL; Marques MB
J Clin Apher; 2013 Dec; 28(6):390-4. PubMed ID: 23857472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
